左乙拉西坦（CAS 102767-28-2）：分子式 C8H14N2O2、分子量 170.21；类别 医药中间体及原料药。
| CAS号 | 102767-28-2 |
|---|---|
| 分子式 | C8H14N2O2 |
| 分子量 | 170.21 |
| 熔点 | 115-119C |
| LogP | -0.6 |
| 应用领域 | Uses: MEDICATION、THERAP CAT: Anticonvulsant、Use (kg) in Switzerland (2009): >2500、Use (kg、approx.) in Germany (2009): >50000、exact) in Germany (2009): 53353、Use (kg) in USA (2002): 29900、Consumption (g per capita) in Switzerland (2009): 0.32、Consumption (g per capita、approx.) in Germany (2009): 0.61、exact) in Germany (2009): 0.65、Consumption (g per capita) in the USA (2002): 0.11、Excretion rate: 0.66、Calculated removal (%): 45.4、Used as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy.、Methods of Manufacturing: Prepn: J. Gobert et al.、EP 162036、eidem、US 4943639 (1985、1990 both to UCB). |
| 类别 | 医药原料 |
登记用途：Uses: MEDICATION、THERAP CAT: Anticonvulsant、Use (kg) in Switzerland (2009): >2500、Use (kg、approx.) in Germany (2009): >50000、exact) in Germany (2009): 53353、Use (kg) in USA (2002): 29900、Consumption (g per capita) in Switzerland (2009): 0.32、Consumption (g per capita、approx.) in Germany (2009): 0.61、exact) in Germany (2009): 0.65、Consumption (g per capita) in the USA (2002): 0.11、Excretion rate: 0.66、Calculated removal (%): 45.4、Used as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy.、Methods of Manufacturing: Prepn: J. Gobert et al.、EP 162036、eidem、US 4943639 (1985、1990 both to UCB).。
左乙拉西坦 是一种医药中间体或原料药类化合物，登记 CAS 号为 102767-28-2，分子式 C8H14N2O2（分子量 170.21），归属于医药中间体及原料药大类化工原料。
登记 CAS 号：102767-28-2
其分子式 C8H14N2O2 由 8 个碳、14 个氢、2 个氮、2 个氧 组成。
别名/同义词：左乙拉西坦 · Levetiracetam
所属分类：医药中间体及原料药
左乙拉西坦 的 CAS 登记号为 102767-28-2。
分子式 C8H14N2O2，分子量 170.21。
别名/同义词：左乙拉西坦、Levetiracetam。
登记用途：Uses: MEDICATION、THERAP CAT: Anticonvulsant、Use (kg) in Switzerland (2009): >2500、Use (kg、approx.) in Germany (2009): >50000、exact) in Germany (2009): 53353、Use (kg) in USA (2002): 29900、Consumption (g per capita) in Switzerland (2009): 0.32、Consumption (g per capita、approx.) in Germany (2009): 0.61、exact) in Germany (2009): 0.65、Consumption (g per capita) in the USA (2002): 0.11、Excretion rate: 0.66、Calculated removal (%): 45.4、Used as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy.、Methods of Manufacturing: Prepn: J. Gobert et al.、EP 162036、eidem、US 4943639 (1985、1990 both to UCB).。
所属分类：医药原料。
左乙拉西坦（CAS 102767-28-2）的独立参考数据，整理自公开化学数据库。
| CAS Registry Number | 102767-28-2 |
|---|---|
| PubChem CID | 5284583 |
| Molecular formula | C8H14N2O2 |
| IUPAC name | (2S)-2-(2-oxopyrrolidin-1-yl)butanamide |
| UNII (FDA) | 44YRR34555 |
| Molecular Weight | 170.21 |
|---|---|
| XLogP3 | -0.3 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 3 |
| Exact Mass | 170.105527694 |
| Monoisotopic Mass | 170.105527694 |
| Topological Polar Surface Area | 63.4 |
| Heavy Atom Count | 12 |
| Melting Point | 115-119C |
|---|---|
| Melting Point | 117 °C |
| Solubility | 104g/100mL |
| Vapor Pressure | 3.5X10-6 mm Hg at 25 °C |
| LogP | -0.6 |
| LogP | -0.65 |
Levetiracetam; 102767-28-2; Keppra; (2S)-2-(2-oxopyrrolidin-1-yl)butanamide; Keppra XR; Spritam; UCB-L 059; ucb L059; matever; Levetiracetame; Levetiracetamum; Levetiracetam teva; UCB-L059; Elepsia; (S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; Levetiracetam sun
| GHS notification summary | 1.7% (2 / 119) |
|---|
| GHS notification summary | 1.7% (2 / 119) |
|---|---|
| Reported hazard statements | H302 (89.1%), H319 (89.1%) |
This chemical does not meet GHS hazard criteria for 1.7% (2 of 119) of reports.
H302 (89.1%): Harmful if swallowed [Warning Acute toxicity, oral]
Levetiracetam · CAS 102767-28-2 · C8H14N2O2. UNII 44YRR34555. Melting Point: 115-119C; Melting Point: 117 °C; Solubility: 104g/100mL.
数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。
English page: Levetiracetam